BPG is committed to discovery and dissemination of knowledge
Articles in Press
8/18/2026 9:30:36 AM | Browse: 12 | Download: 1
Publication Name World Journal of Translational Medicine
Manuscript ID 122119
DOI 10.5528/wjtm.122119
Country India
Category Orthopedics
Manuscript Type Review
Article Title Interleukin-6 and tumour necrosis factor-alpha in osteoimmunology: Aging, and anti-cytokine therapies
Manuscript Source Invited Manuscript
All Author List Arunagiri Gunasekar, Naveen Jeyaraman, Sneha Babu Chitra, Vathani Yudakar, Sanjeevi Bharadwaj, Sathish Muthu and Madhan Jeyaraman
Funding Agency and Grant Number
Corresponding Author Madhan Jeyaraman, Associate Professor, MD, PhD, Researcher, Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Velappanchavadi, Chennai 600077, Tamil Nadu, India. madhanjeyaraman@gmail.com
Key Words Receptor activator of NF-kappa B ligand/osteoprotegerin axis; Janus kinase/nuclear factor kappa B; Osteoprotegerin; Inflammaging; Senolytics
Core Tip Interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) are important cytokines that have been implicated in the pathogenesis of bone loss by means of an imbalance of receptor activator of NF-kappa B ligand/osteoprotegerin, nuclear factor kappa B activation, and osteoclast encouragement. They are aggravated by inflammatory bone diseases and osteoporosis caused by inflammaging and senescence-associated secretory phenotype. Their crosstalk promotes bone resorption by dysregulating immune cells. Anti-TNF-α and anti-IL-6 treatments normalize bone homeostasis, and observational data suggest a lower reduction in fracture occurrence, an estimate that should be interpreted cautiously given its non-randomized basis. These novel methods include senolytics, Janus kinase, and cytokine-based precision medicine.
Citation Gunasekar A, Jeyaraman N, Chitra SB, Yudakar V, Bharadwaj S, Muthu S, Jeyaraman M. Interleukin-6 and tumour necrosis factor-alpha in osteoimmunology: Aging, and anti-cytokine therapies. World J Transl Med 2026; In press
PDF 122119-in-press.pdf
Received
2026-04-10 06:21
Peer-Review Started
2026-04-10 06:22
First Decision by Editorial Office Director
Return for Revision
2026-07-06 01:54
Revised
2026-07-20 07:38
Publication Fee Transferred
Second Decision by Editor
2026-08-18 02:38
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-08-18 09:30
Articles in Press
2026-08-18 09:30
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 2220-6132 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright ©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com